Cancer immunotherapy using checkpoint blockade

5,755 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cholesterol induces CD8+ T-cell exhaustion in the tumor microenvironment (2019, positive): “Unprecedented clinical success in a variety of cancers has been achieved by using antibodies to target immune checkpoints on CD8+ T cells, particularly PD-1 antibodies (Callahan et al., 2016; Ribas and Wolchok, 2018).”
Dysfunctional CD8+ T cells form a proliferative, dynamically regulated compartment within human melanoma (2018, positive): “INTRODUCTION T cell checkpoint blockade therapies that aim to reactivate tumor-specific T cell responses have revolutionized cancer treatment, resulting in durable responses in patients with advanced disease (Ribas and Wolchok, 2018; Sharma and Allison, 2015).”
Pathophysiology of diabetes: An overview (2020, background): “[118,119] Furthermore, immune checkpoint inhibitors, such as ipilimumab, nivolumab, and pembrolizumab, used in cancer immunotherapy for treatment of advanced-stage cancers, including head and neck cancer, renal cancer, urothelial cancers, non-small-cell lung carcinoma, and melanoma besides other can”
Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer (2019, methodology): “For the PARP inhibitor experiments, mice received one of the following treatments: (1) vehicle; (2) olaparib (50 mg/kg daily) 4 times per week; (3) anti–PD-L1 (300 μg) once per week; or (4) combination of olaparib and anti–PD-L1.”